Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23940202 | 0.86 | LMNA (0.46) | BRD4LMNACREBBPHDAC1HDAC2 | |
| SCHEMBL23940222 | 0.85 | KMT2A (0.47) | BRD4LMNACREBBPHDAC1HDAC2 | |
| SCHEMBL23940243 | 0.84 | ALDH1A1 (0.59) | CREBBPHDAC1HDAC2ALDH1A1KDM4E | |
| SCHEMBL23940144 | 0.83 | CREBBP (0.49) | LMNACREBBPHDAC1HDAC2CNR1 | |
| SCHEMBL23940250 | 0.81 | BRD4 (0.71) | BRD4LMNAHDAC1HDAC2NR4A2 | |
| SCHEMBL23940153 | 0.80 | ALDH1A1 (0.50) | NR4A2CNR1CNR2ALDH1A1KDM4E | |
| SCHEMBL23940236 | 0.80 | CREBBP (0.51) | LMNACREBBPALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL15458754 | 0.79 | SMN1; SMN2 (0.51) | BRD4LMNACREBBPALDH1A1KDM4E | |
| SCHEMBL3924368 | 0.79 | ALDH1A1 (0.53) | LMNANR4A2ALDH1A1KDM4EMAPK1 | |
| SCHEMBL13209353 | 0.78 | NR4A2 (0.65) | BRD4LMNANR4A2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323966-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323966-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | TYK2, JAK3, JAK1 | BRD4 753/4885LMNA 4049/4885CREBBP 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.